Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway

• Published in: Medical science monitor 2017-12, Vol.23, p.5793-5802
• Main Authors: Shi, Xuan-Yan, Ding, Wei, Li, Tie-Qiu, Zhang, Yi-Xiong, Zhao, Shan-Chao
• Format: Article
• Language: English
• Subjects: Annexin A5; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Cell Cycle - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Forkhead Box Protein O3 - drug effects; Forkhead Box Protein O3 - metabolism; Histone Deacetylase Inhibitors - metabolism; Histone Deacetylases; Humans; Hydroxamic Acids - metabolism; Hydroxamic Acids - pharmacology; Inhibitor of Apoptosis Proteins; Male; Molecular Biology; Prostatic Neoplasms - drug therapy; Proto-Oncogene Proteins c-akt - drug effects; Signal Transduction - drug effects; Vorinostat; Xenograft Model Antitumor Assays
• ISSN: 1643-3750; 1234-1010; 1643-3750
• DOI: 10.12659/MSM.904597

BACKGROUND Histone deacetylase (HDAC) inhibitors are emerging as a new class of anti-cancer drugs that promote cancer cell apoptosis, and include suberoylanilide hydroxamic acid (SAHA). The aim of this study was to investigate the mechanism of SAHA-induced apoptosis in human prostate cancer cell lines, DU145 and PC-3. MATERIAL AND METHODS Cell lines, DU145 and PC-3, were studied before and after treatment with SAHA. The effects of SAHA treatment on cell proliferation were studied using the MTT cell proliferation assay. Annexin-V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) staining were used to study the effects of SAHA treatment on cell apoptosis. Western blotting, quantitative polymerase chain reaction (qPCR) and short interfering (si)RNA assays were performed to study the effects of SAHA treatment on apoptotic and cell cycle proteins and the Akt/FOXO3a signaling pathway. RESULTS Treatment with SAHA inhibited cell proliferation in human prostate cancer cell lines DU145 and PC-3 cells in a dose-dependent way. Cell cycle analysis and Annexin-V FITC/PI staining showed that treatment with SAHA resulted in G2/M cell cycle arrest and increased cell apoptosis in a dose-dependent way. Also, treatment with SAHA reduced the protein expression levels cyclin B and cyclin A2 and promoted the activation of FOXO3a by inhibiting Akt activation. Western blotting, the siRNA assay, and qPCR showed that FOXO3a, the Bcl-2 family of proteins, survivin, and FasL were involved in SAHA-induced apoptosis in prostate cancer cells grown in vitro. CONCLUSIONS Treatment with SAHA promoted apoptosis via the Akt/FOXO3a signaling pathway in prostate cancer cells in vitro.